The authors showed that such tests can be useful as an adjunct to PSA [in patients with PSA levels in the “gray area” (4–10 ng/mL)] to confirm the need for a prostate biopsy, but they cannot be used as stand-alone tests for diagnosing PCa. The gene discussed is KLK3; the disease is posterior cortical atrophy.